TY - JOUR
T1 - How Effective and Safe Is Bronchial Thermoplasty in "real Life" Asthmatics Compared to Those Enrolled in Randomized Clinical Trials?
AU - Arrigo, Rita
AU - Failla, Giuseppe
AU - Scichilone, Nicola
AU - La Sala, Alba
AU - Galeone, Carla
AU - Battaglia, Salvatore
AU - Benfante, Alida
AU - Facciolongo, Nicola
N1 - Publisher Copyright:
© 2016 Rita Arrigo et al.
PY - 2016
Y1 - 2016
N2 - There is limited information on the efficacy and safety of bronchial thermoplasty (BT) in real life. We evaluated the outcomes of the randomized clinical trials for BT in severe asthmatics, in whom the exclusion criteria were not strictly controlled. A case series of seven asthmatics (M/F: 4/3; age: 54.6 ± 2.9 years) is reported. Subjects had a statistically significant improvement in AQLQ (from a mean of 3.96 ± 1.1 to 4.5 ± 1.2 and 5.5 ± 0.6 after 6 and 12 months of treatment; p = 0.0007) and in the ACQ score (from 2.77 ± 0.8 to 1.83 ± 1.2 and 1.5 ± 0.8 after 6 and 12 months; p < 0.001). In the year after BT, severe exacerbations, salbutamol use, and OCS use were significantly lower compared with the 1-yr pretreatment period (p < 0.001). No ED visits and hospitalization occurred in the year after BT. No changes in functional parameters were recorded. Our investigation confirms the safety and efficacy of BT in severe asthmatics in real life settings.
AB - There is limited information on the efficacy and safety of bronchial thermoplasty (BT) in real life. We evaluated the outcomes of the randomized clinical trials for BT in severe asthmatics, in whom the exclusion criteria were not strictly controlled. A case series of seven asthmatics (M/F: 4/3; age: 54.6 ± 2.9 years) is reported. Subjects had a statistically significant improvement in AQLQ (from a mean of 3.96 ± 1.1 to 4.5 ± 1.2 and 5.5 ± 0.6 after 6 and 12 months of treatment; p = 0.0007) and in the ACQ score (from 2.77 ± 0.8 to 1.83 ± 1.2 and 1.5 ± 0.8 after 6 and 12 months; p < 0.001). In the year after BT, severe exacerbations, salbutamol use, and OCS use were significantly lower compared with the 1-yr pretreatment period (p < 0.001). No ED visits and hospitalization occurred in the year after BT. No changes in functional parameters were recorded. Our investigation confirms the safety and efficacy of BT in severe asthmatics in real life settings.
UR - http://www.scopus.com/inward/record.url?scp=84988702898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988702898&partnerID=8YFLogxK
U2 - 10.1155/2016/9132198
DO - 10.1155/2016/9132198
M3 - Article
C2 - 27672663
AN - SCOPUS:84988702898
SN - 2314-6133
VL - 2016
JO - BioMed research international
JF - BioMed research international
M1 - 9132198
ER -